Académique Documents
Professionnel Documents
Culture Documents
Neoplasms
(C00-D48)
This chapter contains the following blocks:
C00-C97Malignant neoplasms
o C00-C75Malignant neoplasms, stated or presumed to be primary, of specified sites, except
of lymphoid, haematopoietic and related tissue
C00-C14Malignant neoplasms of lip, oral cavity and pharynx
C15-C26Malignant neoplasms of digestive organs
C30-C39Malignant neoplasms of respiratory and intrathoracic organs
C40-C41Malignant neoplasms of bone and articular cartilage
C43-C44Melanoma and other malignant neoplasms of skin
C45-C49Malignant neoplasms of mesothelial and soft tissue
C50-C50Malignant neoplasm of breast
C51-C58Malignant neoplasms of female genital organs
C60-C63Malignant neoplasms of male genital organs
C64-C68Malignant neoplasms of urinary tract
C69-C72Malignant neoplasms of eye, brain and other parts of central nervous system
C73-C75Malignant neoplasms of thyroid and other endocrine glands
o C76-C80Malignant neoplasms of ill-defined, secondary and unspecified sites
o C81-C96Malignant neoplasms, stated or presumed to be primary, of lymphoid,
haematopoietic and related tissue
o C97-C97Malignant neoplasms of independent (primary) multiple sites
D00-D09In situ neoplasms
D10-D36Benign neoplasms
D37-D48Neoplasms of uncertain or unknown behaviour
Notes
Categories C76C80 include malignant neoplasms for which there is no clear indication of
the original site of the cancer or the cancer is stated to be "disseminated", "scattered" or
"spread" without mention of the primary site. In both cases the primary site is considered
to be unknown.
2. Functional activity
All neoplasms are classified in this chapter, whether they are functionally active or not. An
additional code from Chapter IV may be used, if desired, to identify functional activity
associated with any neoplasm. For example, catecholamine-producing malignant
phaeochromocytoma of adrenal gland should be coded to C74 with additional code E27.5;
basophil adenoma of pituitary gland with Cushing syndrome should be coded to D35.2 with
additional code E24.0.
3. Morphology
In Chapter II neoplasms are classified predominantly by site within broad groupings for
behaviour. In a few exceptional cases morphology is indicated in the category and
subcategory titles.
For those wishing to identify the histological type of neoplasm, comprehensive separate
morphology codes are provided (see section Morphology of neoplasms). These morphology
codes are derived from the second edition of International Classification of Diseases for
Oncology (ICDO), which is a dual-axis classification providing independent coding systems
for topography and morphology. Morphology codes have six digits: the first four digits
identify the histological type; the fifth digit is the behaviour code (malignant primary,
malignant secondary (metastatic), in situ, benign, uncertain whether malignant or
benign); and the sixth digit is a grading code (differentiation) for solid tumours, and is also
used as a special code for lymphomas and leukaemias.
Attention is drawn to the special use of subcategory .8 in this chapter [see note 5]. Where
it has been necessary to provide subcategories for "other", these have generally been
designated as subcategory .7.
An example of this is a carcinoma of the stomach and small intestine, which should be
coded to C26.8 (Overlapping lesion of digestive system).
Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g. ectopic
pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
7. Use of the Alphabetical Index in coding neoplasms
In addition to site, morphology and behaviour must also be taken into consideration when
coding neoplasms, and reference should always be made first to the Alphabetical Index
entry for the morphological description.
The introductory pages of Volume 3 include general instructions about the correct use of
the Alphabetical Index. The specific instructions and examples pertaining to neoplasms
should be consulted to ensure correct use of the categories and subcategories in Chapter
II.
It is therefore recommended that agencies interested in identifying both the site and
morphology of tumours, e.g. cancer registries, cancer hospitals, pathology departments
and other agencies specializing in cancer, use ICD-O.